Clinical trials: Demyelinating Disorder
Relapsing Remitting Multiple Sclerosis
Safety of New Formulation of Glatiramer Acetate
The purpose of this study is to compare pain associated with injections and injection-site reactions of the approved formulation of Glatiramer Acetate (GA) versus investigational formulation of GA.
- Trial name
- Song (NCT00947752)
- Testing
- Glatiramer Acetate, Experimental Glatiramer Acetate
- Volunteers
- 147 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Multiple Sclerosis, Overactive Detrusor
Study of Darifenacin in Patients Suffering From Multiple Sclerosis and Neurogenic Detrusor Overactivity
The objective of this study is to explore the effects of darifenacin in patients with multiple sclerosis and neurogenic detrusor overactivity.
- Trial name
- NCT00845338
- Testing
- Darifenacin (BAY79-4998)
- Where
- 15 sites in Germany
- Volunteers
- 7 people
- Sponsor
- Bayer
Primary Progressive Multiple Sclerosis, Multiple Sclerosis, Secondary Progressive
Efficacy, Safety and Tolerability of Andrographolides Versus Placebo in Patients With Progressive Forms of MS
The purpose of this study is to compare the efficacy and safety of andrographolide 140 mg administered twice a day orally versus a placebo as a modifying treatment of the disease in patients with the progressive forms of Multiple…
- Trial name
- NCT02273635
- Testing
- Andrographolides
- Where
- Chile
- Volunteers
- 68 people
- Sponsor
- Innobioscience SpA
Multiple Sclerosis, Relapsing-remitting
Observational Study of Rebismart®2.0 + MSdialog™ in Subjects With Remitting Multiple Sclerosis (ADHERQOL)
This is a 24-month, observational, prospective, multinational, multicenter study to determine the relationship between the relapse (percentage of relapse free subjects) and adherence in subjects diagnosed with RRMS treated with…
- Trial name
- ADHERQOL (NCT02394782)
- Testing
- RebiSmart®2.0, MSdialog™
- Where
- Germany
- Volunteers
- 8 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Multiple Sclerosis
ATX-MS-1467 in Multiple Sclerosis
This is a multi-center, open-label, single arm, baseline-controlled Phase 2a trial to evaluate the clinical and biological effects of ATX-MS-1467 in subjects with relapsing multiple sclerosis (MS) and to assess the maintenance of…
- Trial name
- NCT01973491
- Testing
- ATX-MS-1467
- Where
- Germany
- Volunteers
- 37 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Multiple Sclerosis
Effect of Teriflunomide on Immune Cell Subsets in the Blood of Patients With Multiple Sclerosis
Primary Objective: To measure the effect of Teriflunomide on lymphocytes subsets in patients with relapsing forms of multiple sclerosis as compared with baseline values and those of a reference population of untreated healthy…
- Trial name
- TERI-DYNAMIC (NCT01863888)
- Testing
- teriflunomide HMR1726, cholestyramine, charcoal
- Where
- 10 sites in Belgium, Germany and 1 more
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Sanofi
Relapsing Remitting Multiple Sclerosis
Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)
This is a Phase 2, randomized, rater-blinded, 5-arm, parallel-group trial that will test 4 doses of plovamer acetate against the active comparator Copaxone in subjects with Relapsing Remitting Multiple Sclerosis (RRMS).
- Trial name
- NCT01963611
- Testing
- Plovamer acetate 0.5 milligram (mg), Copaxone 20 mg, Plovamer acetate 3 mg
- Where
- 118 sites in United States, Bulgaria and 15 more
- Volunteers
- 255 people
- Sponsor
- EMD Serono
Multiple Sclerosis, Relapsing-Remitting
Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple Sclerosis
The trial will study 2 doses of Immune Globulin Intravenous (Human), 10% Caprylate/Chromatography Purified (IGIV-C) for the number of relapses that occur in a 1 year treatment period.
- Trial name
- PRIVIG (NCT00220779)
- Testing
- Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified, Albumin (Human) 25%, United States Pharmacopeia (USP)
- Where
- 37 sites in United States, Austria and 10 more
- Volunteers
- 128 people
- Sponsor
- Grifols Therapeutics LLC
Canavan Disease
A Study of AAV9 Gene Therapy in Participants With Canavan Disease (CANaspire Clinical Trial)
The main objective of this trial is to evaluate the safety, tolerability, and pharmacodynamic activity of BBP-812, an investigational AAV9-based gene therapy, in pediatric participants with Canavan disease.
- Trial name
- NCT04998396
- Testing
- AAV9 BBP-812
- Where
- 4 sites in United States
- Volunteers
- 26 people
- Sponsor
- Aspa Therapeutics
Multiple Sclerosis, Relapsing Remitting
BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon
Considering the significance of an early and consequent Multiple Sclerosis (MS) treatment as well as the challenge to achieve high adherence to treatment, evaluating the benefits of any new measure to improve adherence is…
- Trial name
- NCT02247310
- Testing
- Interferon beta-1b (Betaferon®, BAY 86-5046), BETACONNECT
- Where
- 11 sites in Austria, Belgium and 9 more
- Volunteers
- 498 people
- Sponsor
- Bayer
Multiple Sclerosis, Cognitive Impairment
Rivastigmine in Multiple Sclerosis Patients With Cognitive Impairment
This study evaluated the efficacy and safety of 10 cm² rivastigmine patch vs. placebo in cognitively impaired Multiple Sclerosis (MS) patients.
- Trial name
- EXCITING (NCT00881205)
- Testing
- Rivastigmine transdermal patch
- Where
- 49 sites in Germany
- Volunteers
- 86 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
Prospective, Multicenter Non Interventional Study to Evaluate Adherence to Betaferon Over a 2 Years Period
The aim of the SEPLUS study is to evaluate the patients characteristics associated with adherence to Betaferon over a 24-month follow up period after the initiation of Betaferon in the BetaPlus program
- Trial name
- SEPLUS (NCT01076595)
- Testing
- Interferon beta-1b (Betaseron, BAY86-5046)
- Where
- France
- Volunteers
- 73 people
- Sponsor
- Bayer
Relapsing Remitting Multiple Sclerosis
Effectiveness and Safety of Generic Delayed-Release Dimethyl Fumarate (Sclera® or Marovarex ®, Hikma) in Routine Medical Practice in the Treatment of Relapsing-Remitting Multiple Sclerosis in MENA Region
The purpose of this observational study is to evaluate the effectiveness, safety and health related quality of life of Generic DMF (Sclera® or Marovarex ®, Hikma) in patients undergoing routine clinical care for RRMS in MENA…
- Trial name
- NCT04468165
- Testing
- Dimethyl Fumarate (DMF)
- Where
- 6 sites in Algeria, Egypt and 1 more
- Volunteers
- 160 people
- Sponsor
- Hikma Pharmaceuticals LLC
Rare Diseases, Neuromyelitis Optica Spectrum Disorder (NMOSD)
Epidemiological Study of Treatment Approaches on AQP4-IgG Positive NMOSD in Russia
This is a multi-centre, retrospective-prospective, single-arm, non-interventional (observational) cohort study with secondary data collection within real-world settings of participants with AQP4-IgG positive NMOSD.
- Trial name
- NCT07247292
- Where
- Russia
- Volunteers
- 3 people
- Sponsor
- AstraZeneca
Multiple Sclerosis
Proof-of-concept Study for SAR441344 (Frexalimab) in Relapsing Multiple Sclerosis
Primary Objective: To determine the efficacy of SAR441344 as measured by reduction of the number of new active brain lesions Secondary Objective: To evaluate efficacy of SAR441344 on disease activity as assessed by other MRI…
- Trial name
- NCT04879628
- Testing
- SAR441344 IV, SAR441344 SC, MRI contrast-enhancing preparations
- Where
- 37 sites in United States, Bulgaria and 8 more
- Volunteers
- 129 people
- Sponsor
- Sanofi
Multiple Sclerosis, Spasticity
One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity
Clinical protocol OS440-3003 is a multicenter, open-label, non-randomized, uncontrolled, dose escalation study to evaluate the safety and tolerability of Arbaclofen Extended Release Tablets over 1 year in Multiple Sclerosis (MS)…
- Trial name
- NCT01844232
- Testing
- arbaclofen
- Where
- 35 sites in United States, Russia and 1 more
- Volunteers
- 150 people
- Sponsor
- RVL Pharmaceuticals, Inc.
Multiple Sclerosis
An Investigation of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis Patients
A study to compare the efficacy of GW-1000-02 [named Sativex® in Canada and also named Sativex® Oromucosal Spray] with placebo in relieving five key symptoms of Multiple Sclerosis after six weeks of therapy.
- Trial name
- NCT01610700
- Testing
- GW-1000-02
- Where
- United Kingdom
- Volunteers
- 160 people
- Sponsor
- Jazz Pharmaceuticals
Relapsing-remitting Multiple Sclerosis
A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis
This is a double-blind, randomized, active-controlled, parallel group, Phase 1/3 study to compare efficacy, PK, PD and overall safety of CT-P53 with Ocrevus in patients with Relapsing-remitting Multiple Sclerosis.
- Trial name
- NCT05906992
- Testing
- CT-P53, US-Ocrevus, EU-Ocrevus
- Where
- Poland
- Volunteers
- 512 people
- Sponsor
- Celltrion
Multiple Sclerosis
Evaluation of Quality of Life (QoL) in Subjects With Highly Active Relapsing Multiple Sclerosis (MS) (CLARIFY MS)
The main purpose of the study was to assess the health-related quality of life (HRQoL) through the Multiple Sclerosis Quality of Life-54 Questionnaire (MSQoL-54) scale in highly-active relapsing multiple sclerosis (RMS)…
- Trial name
- NCT03369665
- Testing
- Mavenclad®
- Where
- 92 sites in Austria, Belgium and 16 more
- Volunteers
- 485 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Muscle Spasticity
Safety and Preliminary Effectiveness of AV650 in Patients With Spasticity Associated With Multiple Sclerosis
A drug called AV650 (tolperisone HCl) will be given to patients who have spasticity associated with multiple sclerosis. This study has three purposes: 1. To determine whether AV650 is safe for patients with multiple sclerosis; 2.
- Trial name
- NCT00532532
- Testing
- tolperisone HCl
- Where
- 28 sites in Czechia, Germany and 3 more
- Volunteers
- 150 people
- Sponsor
- Avigen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.